Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1523-1739.1995.9051312.x-i1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
What happens when the network fails? A response to telesurgery recommendations and a proposal for a new class of intraoperative complications in telesurgery.
J Robot Surg
September 2025
ORSI Academy, Melle, Belgium.
This Letter to the Editor responds to the recent publication by Patel et al. (J Robot Surg. Jul 11;19(1):370, 2025), which outlines a framework and recommendations for telesurgery.
View Article and Find Full Text PDFMore than pain: Speech, language, neurocognitive, and hearing issues among children with sickle cell disease.
J Natl Med Assoc
September 2025
Communication Equity Outcomes Laboratory, Department of Speech, Language and Hearing Sciences, University of Florida, Gainesville, FL, United States.
Importance: Significant advancements have been made in the management of sickle cell disease (SCD); an inherited blood disorder most prevalent among African Americans. While chronic pain is a hallmark of SCD and has been the primary focus of treatment, contemporary literature highlights the potential presence of developmental issues related to speech, language, neurocognitive, and auditory abilities that are often overlooked in SCD management.
Observations: This paper explores the spectrum of communication-related challenges that specifically affect children with SCD and fall within the scope of practice for speech-language pathologists (SLPs) and audiologists (AUDs).
CRISPR RNP-Mediated Transgene-Free Genome Editing in Plants: Advances, Challenges and Future Directions for Tree Species.
Plant Cell Environ
September 2025
State Key Laboratory of Tree Genetics and Breeding, Co-Innovation Center for Sustainable Forestry in Southern China, Bamboo Research Institute, Key Laboratory of National Forestry and Grassland Administration on Subtropical Forest Biodiversity Conservation, School of Life Sciences, Nanjing Forestry
CRISPR ribonucleoprotein (RNP)-mediated genome editing offers a transgene-free platform for precise genetic modification in diverse herbaceous and tree species, including rice, wheat, apple, poplar, oil palm, rubber tree and grapevine. However, its application in woody plants faces distinct challenges, notably inefficient delivery and regeneration difficulties, particularly in species such as bamboo. While some of these issues also occur in herbaceous plants, they are often significantly more complex in woody species due to factors such as intricate cell wall architecture, widespread recalcitrant genotypes and inherent limitations of current delivery platforms.
View Article and Find Full Text PDFExpert consensus for prevention, diagnosis and management of persistent chemotherapy-induced alopecia.
J Eur Acad Dermatol Venereol
September 2025
Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Background: Persistent chemotherapy-induced alopecia (pCIA) is a distressing side effect of antineoplastic agents, imposing significant psychological burdens on cancer survivors. Despite its impact, there are no standardized guidelines for diagnosis, prevention or management.
Objective: To establish consensus-based definitions, diagnostic criteria, grading systems and management recommendations for pCIA.
Deriving Optimal Treatment Timing for Adaptive Therapy: Matching the Model to the Tumor Dynamics.
Bull Math Biol
September 2025
Wolfson Centre for Mathematical Biology, Mathematical Institute, Oxford, UK.
Adaptive therapy (AT) protocols have been introduced to combat drug resistance in cancer, and are characterized by breaks from maximum tolerated dose treatment (the current standard of care in most clinical settings). These breaks are scheduled to maintain tolerably high levels of tumor burden, employing competitive suppression of treatment-resistant sub-populations by treatment-sensitive sub-populations. AT has been integrated into several ongoing or planned clinical trials, including treatment of metastatic castrate-resistant prostate cancer, ovarian cancer, and BRAF-mutant melanoma, with initial clinical results suggesting that it can offer significant extensions in the time to progression over the standard of care.
View Article and Find Full Text PDF